Last week, readers were most interested in a story about FDA approving Cleveland Diagnostics' prostate cancer test.

The test, which will use Iso-PAS technology, will be developed by Nipro of Japan in collaboration with other companies, institutes, and nonprofit organizations.

The medical center will use PathAI's AISight Dx image management system to evaluate algorithms for a variety of applications.

The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.

Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.

The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.

Of the 30 companies in the index, 25 saw their share prices increase and four saw their stock prices decline, while one company was flat month over month.

NEW YORK – The US Food and Drug Administration on Tuesday released a proposal to reclassify companion diagnostic assays from Class III medical devices to Class II devices. In its proposal in the ...

The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.

Last week, readers were most interested in a story about FDA's plan to reclassify some tests that now require PMAs to require only 510(k) clearance.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.